If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 71 - 80 of 272
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer,
Stomach,
Prostate,
Breast Cancers,
Other Skin,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary,
Head and Neck Cancers,
Thoracic Cancers,
Sarcoma,
Other Urologic,
Pancreas/Liver,
Cervix,
Gynecologic Cancers,
Esophagus,
Melanoma, Skin,
Bladder,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Skin Cancers
WATCHMAN FLX Pro Left Atrial Appendage Closure Device With Alternative Post-Implant Monotherapy
Objective
SIMPLAAFY Clinical Trial
Protocol No
CVC-BOSTONSCI-SIMPLAAFY
Categories
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects with Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer
Objective
A Phase 1B Study of Neoadjuvant Xaluritamig Therapy in Patients with Newly Diagnosed Localized Intermediate or High Risk Prostate Cancer
Protocol No
AMGEN-AMG-509-20230237
Categories
A Phase 2 Study of Epcoritamab and Rituximab for First-Line Treatment of Follicular Lymphoma
Objective
A phase 2 study of Epcoritamab and Rituximab for first-line treatment of follicular lymphoma.
Protocol No
DFCI-22-702
Categories
A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for t
Objective
Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Protocol No
GI-TAKEDA-VICTRIVA
Categories
A Phase 2 Study with Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment Naïve Pancreas Adenocarcinoma
Objective
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Protocol No
COLUMBIA-S9513-CHEMO4METPANC
Categories
Single-Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants (TRANSPARENT)
Objective
Study of toripalimab for recurrent metastatic nasopharyngeal carcinoma treatment naive patients
Protocol No
RTOG-FND-3521-CHS-007-01
Categories
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Ac
Objective
Study of quizartinib combined with chemo as maintenance for newly diagnosed AML patients
Protocol No
DAIICHI-AC220-168
Categories
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia
Objective
Study of ziftomenib combinations in patients with R/R AML
Protocol No
KURA-KO-MEN-008
Categories
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203